FDA Cites ProRx LLC in 2026-04-07 Warning Letter — Compounding Pharmacy/Adulterated Drug Products
Letter issued · posted to fda.gov .
Subject as published: Compounding Pharmacy/Adulterated Drug Products
TL;DR
FDA issued a Warning Letter to ProRx LLC on 2026-04-07 citing: Compounding Pharmacy/Adulterated Drug Products. Full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prorx-llc-723704-04072026
Argus analysis
ProRx LLC (MARCS-CMS 723704) received an FDA Warning Letter dated April 7, 2026 from the Center for Drug Evaluation and Research (CDER). The letter cites: Compounding Pharmacy/Adulterated Drug Products. FDA posts Warning Letters to fda.gov after an internal review period; this one was made public on May 12, 2026.
Compounding letters typically cite section 503A (traditional compounding) or 503B (outsourcing facilities) of the FD&C Act, frequently combined with CGMP or insanitary-conditions findings. FDA distinguishes compounders from manufacturers largely on production scale and patient-specific prescriptions — a distinction these letters often argue the firm has exceeded.
FDA Warning Letters typically specify a 15-working-day response window for the recipient to detail corrective actions. Compliance teams at peer companies in the same compounding pharmacy category commonly use a newly published letter as a prompt to re-check their own procedures against the same citation, and to watch fda.gov for a close-out letter confirming the cited firm's corrective action was accepted — or, absent one, for escalation to import alert, injunction, or product seizure.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Compounding letters typically cite Section 503A (FDCA) for traditional compounders or Section 503B for outsourcing facilities, frequently combined with insanitary-conditions findings.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER ProRx LLC MARCS-CMS 723704 — April 07, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Recipient Name Arthur Fletcher Recipient Title General Counsel ProRx LLC 619 Jeffers Cir Exton , PA 19341-2540 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States WARNING LETTER WL # 723704 April 7, 2026 Dear Mr. Fletcher: You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b] 1 on April 27, 2022, and most recently on February 20, 2026. From September 9, 2025, to September 19, 2025, an FDA investigator inspected your facility, ProRx LLC, located at 619 Jeffers Cir, Exton, PA 19341. During the inspection, the investigator noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk. FDA issued a Form FDA 483 to your facility on September 19, 2025, and an amended Form FDA 483 on October 10, 2025. We reviewed your October 24, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence on February 13, 2026. FDA also acknowledges that, on October 15, 2025, your firm initiated a voluntary recall of Lot PRORX08062025-3 of Tirzepatide Injection 27mg/3mL, 3mL in multidose vials and various lots of Semaglutide Injection multidose vials in multiple strengths, within expiry, due to a lack of sterility assurance. Based on this inspection, it appears you produced drugs that violate the FDCA. A. Compounded Drug Products under the FDCA Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met. 2 An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable pro…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a Compounding (503A) warning letter?
- Compounding letters typically cite Section 503A (FDCA) for traditional compounders or Section 503B for outsourcing facilities, frequently combined with insanitary-conditions findings.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has ProRx LLC had FDA enforcement actions before?
- Yes. Argus HQ has recorded 2 total FDA actions tied to ProRx LLC: 1 warning letter, 0 recalls, and 0 approval records.
- What FDA violations was ProRx LLC cited for?
- The FDA Warning Letter to ProRx LLC (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Compounding Pharmacy/Adulterated Drug Products. Classification: Compounding (503A).
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites ProRx LLC in 2026-04-07 Warning Letter — Compounding Pharmacy/Adulterated Drug Products. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-prorx-llc-2026-04-07-compounding
"FDA Cites ProRx LLC in 2026-04-07 Warning Letter — Compounding Pharmacy/Adulterated Drug Products." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-prorx-llc-2026-04-07-compounding.
Argus HQ Research. "FDA Cites ProRx LLC in 2026-04-07 Warning Letter — Compounding Pharmacy/Adulterated Drug Products." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-prorx-llc-2026-04-07-compounding.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_prorx_llc_2026_04_07_compounding_2026,
title = {FDA Cites ProRx LLC in 2026-04-07 Warning Letter — Compounding Pharmacy/Adulterated Drug Products},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-prorx-llc-2026-04-07-compounding},
note = {Accessed: July 13, 2026}
}